Market closed
Sanofi/€SAN
08:00
10:10
12:15
14:25
16:30
1D1W1MYTD1Y5YMAX
About Sanofi
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, over-the-counter treatments and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 20% of total sales, but profits are shared with Regeneron. Just over 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Ticker
€SAN
Sector
Trading on
PAR
Industry
Pharmaceuticals
Headquarters
Employees
82,878
Website
Sanofi Metrics
BasicAdvanced
€130B
23.30
€4.44
0.46
€3.76
3.63%
Price and volume
Market cap
€130B
Beta
0.46
52-week high
€105.58
52-week low
€85.07
Average daily volume
1.6M
Dividend rate
€3.76
Financial strength
Current ratio
1.46
Quick ratio
0.28
Long term debt to equity
17.216
Total debt to equity
22.944
Dividend payout ratio (TTM)
84.60%
Interest coverage (TTM)
8.45%
Management effectiveness
Return on assets (TTM)
4.37%
Return on equity (TTM)
7.53%
Valuation
Price to earnings (TTM)
23.297
Price to revenue (TTM)
2.923
Price to book
1.68
Price to tangible book (TTM)
6.54
Price to free cash flow (TTM)
21.996
Dividend yield (TTM)
3.63%
Forward dividend yield
3.63%
Growth
Revenue change (TTM)
-3.80%
Earnings per share change (TTM)
6.75%
3-year revenue growth (CAGR)
4.17%
3-year earnings per share growth (CAGR)
-2.49%
3-year dividend per share growth (CAGR)
5.59%
What the Analysts think about Sanofi
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Sanofi stock.
Sanofi Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Sanofi Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Sanofi News
AllArticlesVideos
Press Release: ECCO 2025: new duvakitug data reinforce best-in-class potential in ulcerative colitis and Crohn's disease
GlobeNewsWire·8 hours ago
Sanofi: OpenAI's Research Agents Could Lead To Explosive Growth
Seeking Alpha·3 days ago
Press Release: Sanofi and CD&R sign Opella share purchase agreement
GlobeNewsWire·3 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe
FAQs
What’s the current market cap for Sanofi stock?
Sanofi (SAN) has a market cap of €130B as of February 22, 2025.
What is the P/E ratio for Sanofi stock?
The price to earnings (P/E) ratio for Sanofi (SAN) stock is 23.3 as of February 22, 2025.
Does Sanofi stock pay dividends?
Yes, the Sanofi (SAN) stock pays dividends to shareholders. As of February 22, 2025, the dividend rate is €3.76 and the yield is 3.63%. Sanofi has a payout ratio of 84.6% on a trailing twelve-month basis.
When is the next Sanofi dividend payment date?
The next Sanofi (SAN) dividend payment date is unconfirmed.
What is the beta indicator for Sanofi?
Sanofi (SAN) has a beta rating of 0.46. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.